EUVIMEDEUVIMED entdecken
Open Access

Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Stent Implantation

Seung-Jun Lee iD, Jaehyeong Cho, Jihye Shin iD, Sung-Jin Hong iD, Chul-Min Ahn iD, Jung-Sun Kim iD, Young-Guk Ko iD, Donghoon Choi iD, Myeong-Ki Hong iD, Seng Chan You, Byeong-Keuk Kim iD

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.124.034862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Seung-Jun Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Severance Cardiovascular Hospital Yonsei University, College of Medicine Seoul South Korea. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Dual Anti-Platelet Therapy, Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

After coronary stent implantation, prolonged dual antiplatelet therapy (DAPT) increases bleeding risk, requiring personalization of DAPT duration. The aim of this study was to develop and validate a machine learning model to predict optimal DAPT duration after contemporary drug‐eluting stent implantation in patients with coronary artery disease. Methods and Results The One‐Month DAPT, RESET (Real Safety and Efficacy of 3‐Month Dual Antiplatelet Therapy Following Endeavor Zotarolimus‐Eluting Stent Implantation), and IVUS‐XPL (Impact of Intravascular Ultrasound Guidance on Outcomes of Xience Prime Stents in Long Lesion) trials provided a derivation cohort (n=6568). Using the X‐learner approach, an individualized DAPT score was developed to determine the therapeutic benefit of abbreviated (1–6 months) versus standard (12‐month) DAPT using various predictors. The primary outcome was major bleeding; the secondary outcomes included 1‐year major adverse cardiac and cerebrovascular events and 1‐year net adverse clinical events. The risk reduction with abbreviated DAPT (3 months) in the individualized DAPT–determined higher predicted benefit group was validated in the TICO (Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus‐Eluting Stent for Acute Coronary Syndrome) trial (n=3056), which enrolled patients with acute coronary syndrome treated with ticagrelor. The validation cohort comprised 1527 abbreviated and 1529 standard DAPT cases. Major bleeding occurred in 25 (1.7%) and 45 (3.0%) patients in the abbreviated and standard DAPT groups, respectively. The individualized DAPT score identified 2582 (84.5%) participants who would benefit from abbreviated DAPT, which was significantly associated with a lower major bleeding risk (absolute risk difference [ARD], 1.26 [95% CI, 0.15–2.36]) and net adverse clinical events (ARD, 1.59 [95% CI, 0.07–3.10]) but not major adverse cardiac and cerebrovascular events (ARD, 0.63 [95% CI, −0.34 to 1.61]), compared with standard DAPT in the higher predicted benefit group. Abbreviated DAPT had no significant difference in clinical outcomes of major bleeding (ARD, 1.49 [95% CI, −1.74 to 4.72]), net adverse clinical events (ARD, 2.57 [95% CI, −1.85 to 6.99]), or major adverse cardiac and cerebrovascular events (ARD, 1.54 [95% CI, −1.26 to 4.34]), compared with standard DAPT in the individualized DAPT–determined lower predicted benefit group.

Conclusions

Machine learning using the X‐learner approach identifies patients with acute coronary syndrome who may benefit from abbreviated DAPT after drug‐eluting stent implantation, laying the groundwork for personalized antiplatelet therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Eluting StentsDual Anti-Platelet TherapyPlatelet Aggregation InhibitorsPercutaneous Coronary InterventionCoronary Artery DiseaseMachine LearningHemorrhageHumansFemaleMaleMiddle AgedAgedTime FactorsTreatment OutcomeRisk AssessmentDrug Administration ScheduleRisk Factors

Stichwörter der Autor:innen

drug‐eluting stentsdual antiplatelet therapymachine learningpercutaneous coronary interventiontreatment effect heterogeneity

Substanzen

Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Severance Cardiovascular Hospital Yonsei University, College of Medicine Seoul South Korea.
  • Department of Research Keimyung University Dongsan Medical Center Daegu South Korea.
  • Department of Research Health Insurance Review & Assessment Service Wonju South Korea.
  • Department of Biomedical Systems Informatics Yonsei University, College of Medicine Seoul South Korea.
  • Institute for Innovation in Digital Healthcare, Severance Hospital Seoul South Korea.

ORCID-Profile: Seung-Jun Lee, Jihye Shin, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Byeong-Keuk Kim

Zitieren

APA

Lee, S. J., Cho, J., Shin, J., Hong, S. J., Ahn, C. M., Kim, J. S., Ko, Y. G., Choi, D., Hong, M. K., You, S. C., & Kim, B. K. (2024). Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Stent Implantation. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.034862

Vancouver

Lee SJ, Cho J, Shin J, Hong SJ, Ahn CM, Kim JS, et al. Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Stent Implantation. Journal of the American Heart Association. 2024. doi:10.1161/jaha.124.034862

BibTeX
@article{Lee2024,
  author = {Lee, Seung-Jun and Cho, Jaehyeong and Shin, Jihye and Hong, Sung-Jin and Ahn, Chul-Min and Kim, Jung-Sun and Ko, Young-Guk and Choi, Donghoon and Hong, Myeong-Ki and You, Seng Chan and Kim, Byeong-Keuk},
  title = {Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Stent Implantation},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.124.034862}
}
Kostenlos starten →